Abstract 1441P
Background
The accurate detection of lymph node metastasis (LNM) in early gastric cancer (EGC) remains a challenge, conventional radical gastrectomy may not be warranted for EGC patients with a low LNM risk and a favorable prognosis. This study aims to construct a risk prediction model of lymph node metastasis based on clinicopathologic features, tumor budding, convolutional neural network, and machine learning in early gastric cancer.
Methods
Clinicopathological features and tumor budding (TB) were assessed using the image recognition software Qupath. There was a total of 1523471 patches, 260998 patches, and 166594 patches from three patient cohorts that were retrospectively analyzed. Convolutional neural networks (CNNs) were used for deep transfer learning to classify patches and extract features. LASSO regression and multiple machine learning algorithms were employed to combine CNN features with clinicopathological features. The risk prediction model was also verified in two independent validation cohorts.
Results
Among 200 patients, LNM incidence was 27.14% in the training cohort, 15.15% in the internal validation cohort, and 14.82% in the external validation cohort. Multivariate analysis identified pathological T stage and ITBCC-TB grade as independent LNM risk factors (p < 0.05). The Resnet152 CNN model demonstrated excellent performance with AUC values of 0.995, 0.988, and 0.965 in the training, internal validation, and external validation cohorts, respectively. The CNN-ML model using Gradient Boosting exhibited superior predictive capacity, with AUC values of 0.901 (95% CI 0.844-0.957), 0.871 (95% CI 0.726-0.999), and 0.804 (95% CI 0.555-0.999) in the training and two independent validation cohorts.
Conclusions
Pathological T stage and ITBCC-TB grade were identified as independent risk factors for LNM in EGC. The integration of clinicopathological features, image recognition, and deep transfer learning using CNNs resulted in a highly accurate predictive model for LNM in EGC. This model will provide valuable insights into the development of a more comprehensive and individualized approach to managing EGC, thereby improving the quality of care for affected patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1929P - Dabrafenib and trametinib (D+T) in BRAFV600E differentiated thyroid cancer: A real-world experience in Italy
Presenter: Laura Locati
Session: Poster session 18
1930P - Resensitization of BRAF-mutated radioactive iodine refractory differentiated thyroid cancer with longer duration of dabrafenib and trametinib
Presenter: Jiaxin Niu
Session: Poster session 18
1931P - Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
Presenter: Winston Wong
Session: Poster session 18
1932P - Tyrosine kinase inhibitors-induced erythrocytosis in thyroid cancers: A novel safety signal from a retrospective study
Presenter: Silvia Marchesi
Session: Poster session 18
1933P - Utility of circulating tumoral DNA analysis by multi-gene NGS panels in tracking therapy progression of advanced sporadic medullary thyroid carcinoma
Presenter: Raffaele Ciampi
Session: Poster session 18
1934P - Active surveillance for higher-risk papillary thyroid carcinoma in China: A 10-year retrospective study
Presenter: Yan Hu
Session: Poster session 18
1935P - Sequence matters: Impact of first-line response in overall therapeutic outcome in differentiated thyroid cancer. Data from the Spanish national registry of thyroid cancer (REGETNE-Tiroides)
Presenter: Sergio Pérez Fernandez
Session: Poster session 18
1936P - Treatment outcomes of patients with anaplastic thyroid carcinoma (atc): Multicentric data from spanish national registry (regetne-tiroides)
Presenter: José Miguel Rodellar
Session: Poster session 18